UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/694,075	10/27/2003	Ekambar R. Kandimalla	HYB-005US6	3779
99488 Furman Gregor	7590 02/24/201 y Deptula	EXAMINER		
215 Main Stree		HORNING, MICHELLE S		
Suite 101 Biddeford, ME	04005		ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			02/24/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/694,075	KANDIMALLA ET AL.	
Office Action Summary	Examiner	Art Unit	
	MICHELLE HORNING	1648	
The MAILING DATE of this communication ap Period for Reply	opears on the cover sheet with the	e correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPI WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the maili earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIOn 136(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	DN. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).	
Status			
1) ☐ Responsive to communication(s) filed on 13. 2a) ☐ This action is FINAL . 2b) ☐ Th 3) ☐ Since this application is in condition for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matters, p		
Disposition of Claims			
4) ☐ Claim(s) <u>25</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdress 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) <u>25</u> is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/	awn from consideration.		
Application Papers			
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) acceptable and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examin 11.	ecepted or b) objected to by the edrawing(s) be held in abeyance. Sometion is required if the drawing(s) is contained in the drawing(s) is contained in the drawing(s) is contained in the drawing(s).	ee 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the pri application from the International Burea * See the attached detailed Office action for a list	nts have been received. nts have been received in Applica ority documents have been recei au (PCT Rule 17.2(a)).	ation No ved in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)		
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informa 6) Other:		

DETAILED ACTION

This action is responsive to communication filed 12/13/2010.

Claim 25 is under current examination.

Any rejection(s) and/or objection(s) not reiterated herein have been withdrawn.

To allow entry of the rejection(s) below, this action is made non-final.

Response to Arguments

Applicant's arguments, see p. 1-2, filed 12/13/2010, with respect to the rejection(s) of claim(s) 25 under USC 102 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Zhao et al. (2000).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000.

Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claim 25 is rejected under 35 U.S.C. 102(a) as being anticipated by Zhao et al. (*Bioorg Med Chem Lett.* 2000 May 15;10(10):1051-4-previously cited).

The claim is drawn to (in part): a method for modulating the immunostimulatory effect of an immunostimulatory oligonucleotide compound, comprising introducing into the oligonucleotide a 2'-5' linkage.

Zhao et al. discloses a method for modulating the immunostimulatory activity of a CpG-containing sequence, comprising introducing into the oligonucleotide a 3'-O-methylribonucleoside "which would also result in 2'-5' linkage"; see at least p. 1051, col. 2.

Thus, Zhao et al. anticipates the claimed invention.

Claim 25 is rejected under 35 U.S.C. 102(e) as being anticipated by US

Patent 6815429 (hereinafter as "Agrawal"). Note that this patent claims priority to

provisional application 60/178562 filed 1/26/2000 wherein a 2'-5' linkage is described on at least p. 4, para. 4.

The applied reference has a common inventor with the instant application.

Based upon the earlier effective U.S. filling date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Art Unit: 1648

Agrawal describes a method for modulating the immunostimulatory effect of a CpG-containing oligonucleotide via creating a 2'-5'-linkage; see col. 2, lines 64+-col. 4.

Thus, Agrawal anticipates the claimed invention.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 25 is rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 7276489.

Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a CpG-containing sequence further comprising a linker, including a 2'-5' linkage, 2'-O-propargylribose, C3 linker and an amino linker or to a method of introducing such a linker.

Claim 25 is rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 7329648.

Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a method of introducing a linker to a CpG-containing sequence, including a 2'-5' linkage.

Claim 25 is rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 7812000.

Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a CpG-containing sequence further comprising a linker, including a 2'-5' linkage, 2'-O-propargylribose, C3 linker and an amino linker or to a method of introducing such a linker.

Claim 25 is rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 7851453.

Application/Control Number: 10/694,075 Page 6

Art Unit: 1648

Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to a CpG-containing sequence further comprising a linker, including a 2'-5' linkage, 2'-O-propargylribose, C3 linker and an amino linker or to a method of introducing such a linker.

Conclusion

No claim is allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHELLE HORNING whose telephone number is (571)272-9036. The examiner can normally be reached on Monday-Friday 8:00-5:00 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, ZACHARIAH LUCAS can be reached on 571-272-0905. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/694,075

Page 7

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/M. H./ Examiner, Art Unit 1648

/Zachariah Lucas/ Supervisory Patent Examiner, Art Unit 1648